All about health

Allied Market Research published a report, titled, "Electroceuticals/Bioelectric Medicine Market by Product (Cardiac Pacemakers and Implantable Cardioverter Defibrillators, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Vagus...

Allied Market Research published a report, titled, "Inhaled Nitric Oxide Market by Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, and Others): Global Opportunity Analysis and...

Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production...

The report titled "Diaphragm Pumps Market by Mechanism (Air-Operated, Electrical-Operated), Operation (Double Acting, Single Acting), Discharge Pressure, End-User - Global Forecast 2024-2030" is now available on 360iResearch.com's offering, presents...

ImmunityBio, Inc. , an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of patients with...

Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed  Pre-A and Pre-A+ financing with a total of approximately $20 million. This Pre-A round is led by...

PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today that the Company's U.S. subsidiary, Wincal Biopharm, Inc....

Vanda Pharmaceuticals Inc. (Vanda) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex...

Globe Life Inc. announces the live audio webcast of its 2024 Annual Meeting of Shareholders, on Thursday, April 25, 2024 at 10:00 a.m. CDT....

TGH North, a division of Tampa General Hospital, announced its new TGH Brooksville and TGH Spring Hill board of managers, which will serve as a guide for leadership and oversee operations. The board convened Wednesday in Brooksville for its inaugural...

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual...

DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, dry age-related...

Veracyte, Inc. announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and...

SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on its novel Gene Codingtm technology, today announced that four abstracts, including one oral presentation, will be...

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene &...

Cartesian Therapeutics, Inc. (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported twelve-month follow-up data from its Phase 2a trial of Descartes-08 in...

Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual Meeting being held May 7-11, 2024, in-person...

Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene...

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at...

Johnson & Johnson will participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the...

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting 10 posters sharing new preclinical data from...

Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data will be presented on Friday, May 10,...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an...

ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, today announced that it will present new ex vivo...

Carisma Therapeutics Inc.  ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the acceptance of two...

Company unveils Parkinson's disease associated with GBA mutations (PD-GBA) program; two oral presentations feature new data from Capsida's wholly owned programs in PD-GBA and genetic epilepsy due to STXBP1 mutations; both programs in IND-enabling...

Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that new...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced acceptance of two oral presentations at the upcoming...

Bolt Medical, Inc., a clinical stage medical device company is developing a new generation intravascular lithotripsy (IVL) advanced laser-based platform with inherent advantages over commercially available IVL devices for the treatment of calcified...

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced a poster presentation at the American Society of Gene & Cell Therapy...